<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Caribou Biosciences Inc — News on 6ix</title>
    <link>https://6ix.com/company/caribou-biosciences-inc</link>
    <description>Latest news and press releases for Caribou Biosciences Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/caribou-biosciences-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835591778dffbe2df0eae31.webp</url>
      <title>Caribou Biosciences Inc</title>
      <link>https://6ix.com/company/caribou-biosciences-inc</link>
    </image>
    <item>
      <title>Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rmat-designation-to-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rmat-designation-to-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD</description>
    </item>
    <item>
      <title>Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-71</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-71</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing</description>
    </item>
    <item>
      <title>Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/watchmaker-genomics-licenses-crispr-cas9-intellectual-property-from-caribou-biosciences-to-increase-throughput-and-reduce-sequencing-cost-per-sample</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/watchmaker-genomics-licenses-crispr-cas9-intellectual-property-from-caribou-biosciences-to-increase-throughput-and-reduce-sequencing-cost-per-sample</guid>
      <pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
      <description>BOULDER, Colo., February 17, 2026--Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing,</description>
    </item>
    <item>
      <title>Caribou Biosciences to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-participate-upcoming-investor-210500769</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-participate-upcoming-investor-210500769</guid>
      <pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
      <description>BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: Citi 2026 Virtual Oncology Leadership Summit, VirtualFebruary 19, 2026, with a fireside chat at 10:45 AM ET Leerink Global Healthcare Conference, Miami, FLMarch 10, 2026, with a fireside chat at 8:00 AM ETWebcast For more information and link to the</description>
    </item>
    <item>
      <title>Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-breaking-presentations-130000093</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-breaking-presentations-130000093</guid>
      <pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
      <description>Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy and durability that is on par with autologous CAR-T cell therapy in 2L LBCL patients CB-011 CaMMouflage phase 1 translational and clinical data correlate CAR-T cell expansion with deep, durable responses and support the regimen selected for dose expansion BERKELEY, Calif., Feb. 0</description>
    </item>
    <item>
      <title>Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-host-person-virtual-210500263</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-host-person-virtual-210500263</guid>
      <pubDate>Mon, 01 Dec 2025 21:05:00 GMT</pubDate>
      <description>KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will host an expert physician panel discussion during an ancillary event at the 67th American Society of Hemat</description>
    </item>
    <item>
      <title>Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-third-quarter-210500764</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-third-quarter-210500764</guid>
      <pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
      <description>Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for LBCLCB-011 CaMMouflage phase 1 data demonstrate deep, durable responses and manageable safety, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for r/r multiple myeloma$159.2 million in cash, cash equivalents, and marketable securities as</description>
    </item>
    <item>
      <title>Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-positive-data-120000438</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-positive-data-120000438</guid>
      <pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
      <description>First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 202692% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimenConference call and webcast scheduled for today at 8:00 am ET BERKELEY,</description>
    </item>
    <item>
      <title>Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-positive-data-120000909</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-positive-data-120000909</guid>
      <pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
      <description>Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vispa-cel (N=35) 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort (N=22)86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=3</description>
    </item>
    <item>
      <title>Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-host-webcast-report-210000459</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-host-webcast-report-210000459</guid>
      <pubDate>Sun, 02 Nov 2025 21:00:00 GMT</pubDate>
      <description>BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new data from the ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lympho</description>
    </item>
    <item>
      <title>Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-participate-citi-2025-200500068</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-participate-citi-2025-200500068</guid>
      <pubDate>Mon, 25 Aug 2025 20:05:00 GMT</pubDate>
      <description>BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 at 2:30 PM EDT. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available</description>
    </item>
    <item>
      <title>Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-second-quarter-200500449</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-second-quarter-200500449</guid>
      <pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
      <description>-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the second quarter 2025 and provided a business update for its</description>
    </item>
    <item>
      <title>Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-participate-jefferies-global-200000398</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-participate-jefferies-global-200000398</guid>
      <pubDate>Wed, 28 May 2025 20:00:00 GMT</pubDate>
      <description>BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou we</description>
    </item>
    <item>
      <title>Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-first-quarter-200500329</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-first-quarter-200500329</guid>
      <pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
      <description>-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for its</description>
    </item>
    <item>
      <title>Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-participate-bofa-securities-200000854</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-participate-bofa-securities-200000854</guid>
      <pubDate>Tue, 06 May 2025 20:00:00 GMT</pubDate>
      <description>BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Carib</description>
    </item>
    <item>
      <title>Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-strategic-pipeline-201500244</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-announces-strategic-pipeline-201500244</guid>
      <pubDate>Thu, 24 Apr 2025 20:15:00 GMT</pubDate>
      <description>-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 CaMMouflage r/r MM Phase 1 dose escalation dataset expect</description>
    </item>
    <item>
      <title>Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-fourth-quarter-200500056</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-reports-fourth-quarter-200500056</guid>
      <pubDate>Mon, 10 Mar 2025 20:05:00 GMT</pubDate>
      <description>-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2026 -- BERKELEY, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company</description>
    </item>
    <item>
      <title>Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-initiates-the-cb-010-gallop-phase-1-trial-in-lupus-and-provides-outlook-for-multiple-clinical-datasets-in-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-initiates-the-cb-010-gallop-phase-1-trial-in-lupus-and-provides-outlook-for-multiple-clinical-datasets-in-2025</guid>
      <pubDate>Sun, 12 Jan 2025 05:00:00 GMT</pubDate>
      <description>-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at</description>
    </item>
    <item>
      <title>Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-to-present-at-43rd-annual-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-to-present-at-43rd-annual-jp-morgan-healthcare-conference</guid>
      <pubDate>Tue, 07 Jan 2025 05:00:00 GMT</pubDate>
      <description>BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical</description>
    </item>
    <item>
      <title>Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer</title>
      <link>https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-appoints-sri-ryali-as-chief-financial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/caribou-biosciences-inc/news/caribou-biosciences-appoints-sri-ryali-as-chief-financial-officer</guid>
      <pubDate>Thu, 02 Jan 2025 05:00:00 GMT</pubDate>
      <description>BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical</description>
    </item>
  </channel>
</rss>